Clinical Neuroscience of ECT (CNECT)

 Out on PubMed, from investigators in the USA, is this paper: Electric Field, Ictal Theta Power, and Clinical Outcomes in Electroconvulsive Therapy. Miller J, Jones T, Upston J, Deng ZD, McClintock SM, Erhardt E, Farrar D, Abbott CC. Biol Psychiatry Cogn Neurosci Neuroimaging. 2023 Mar 14:S2451-9022(23)00062-9. doi: 10.1016/j.bpsc.2023.03.001. Online ahead of print. PMID:  36925066 The abstract is copied below: Background: Electroconvulsive therapy (ECT) is efficacious for treatment resistant depression. Treatment-induced cognitive impairment can adversely impact functional outcomes. Our pilot study linked the electric field to ictal theta power from a single suprathreshold treatment and ictal theta power to changes in phonemic fluency. In this study, we set out to replicate our findings and expand upon the utility of ictal theta power as a potential cognitive biomarker. Methods: Twenty-seven subjects (nine male and eighteen female) received right unilateral ECT for treatment resistant

 Out on PubMed, from researchers in New Mexico and the NIMH is this paper in JECT: Ictal Theta Power as an Electroconvulsive Therapy Safety Biomarker: A Pilot Study. Miller J, Jones T, Upston J, Deng ZD, McClintock SM, Ryman S, Quinn D, Abbott CC. J ECT. 2022 Jun 1;38(2):88-94. doi: 10.1097/YCT.0000000000000812. PMID:  35613008 The abstract is copied below: Objective: Electroconvulsive therapy (ECT) remains the benchmark for treatment resistant depression, yet its cognitive adverse effects have a negative impact on treatment. A predictive safety biomarker early in ECT treatment is needed to identify patients at cognitive risk to maximize therapeutic outcomes and minimize adverse effects. We used ictal electroencephalography frequency analysis from suprathreshold treatments to assess the relationships between ECT dose, ictal power across different frequency domains, and cognitive outcomes. Methods: Seventeen subjects with treatment resistant depression received right unilateral ECT. Str